US4868111A - Gram-positive expression control sequences - Google Patents
Gram-positive expression control sequences Download PDFInfo
- Publication number
- US4868111A US4868111A US07/875,437 US87543786A US4868111A US 4868111 A US4868111 A US 4868111A US 87543786 A US87543786 A US 87543786A US 4868111 A US4868111 A US 4868111A
- Authority
- US
- United States
- Prior art keywords
- rbsii
- sequence
- promoter
- group
- subtilis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000014509 gene expression Effects 0.000 title abstract description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 90
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 77
- 239000013604 expression vector Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 23
- 238000013518 transcription Methods 0.000 claims abstract description 23
- 230000035897 transcription Effects 0.000 claims abstract description 22
- 230000005030 transcription termination Effects 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 78
- 241000588724 Escherichia coli Species 0.000 claims description 36
- 108091008146 restriction endonucleases Proteins 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 25
- 239000013605 shuttle vector Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 230000010076 replication Effects 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 239000013599 cloning vector Substances 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 41
- 230000005026 transcription initiation Effects 0.000 abstract description 16
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000013612 plasmid Substances 0.000 description 71
- 108020004414 DNA Proteins 0.000 description 57
- 230000001580 bacterial effect Effects 0.000 description 31
- 229960005091 chloramphenicol Drugs 0.000 description 31
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 31
- 239000012634 fragment Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 29
- 238000001962 electrophoresis Methods 0.000 description 26
- 238000010276 construction Methods 0.000 description 24
- 230000004927 fusion Effects 0.000 description 17
- 238000002844 melting Methods 0.000 description 17
- 230000008018 melting Effects 0.000 description 17
- 239000011543 agarose gel Substances 0.000 description 16
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 16
- 229960005542 ethidium bromide Drugs 0.000 description 16
- 229920000936 Agarose Polymers 0.000 description 15
- 241000193830 Bacillus <bacterium> Species 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 10
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 229930027917 kanamycin Natural products 0.000 description 10
- 229960000318 kanamycin Drugs 0.000 description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 10
- 229930182823 kanamycin A Natural products 0.000 description 10
- 239000006142 Luria-Bertani Agar Substances 0.000 description 8
- 108020005038 Terminator Codon Proteins 0.000 description 8
- 101150055766 cat gene Proteins 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 7
- 101150074155 DHFR gene Proteins 0.000 description 5
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 5
- 108020001096 dihydrofolate reductase Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091006629 SLC13A2 Proteins 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 3
- 229960001082 trimethoprim Drugs 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229910003798 SPO2 Inorganic materials 0.000 description 2
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- YYMQZXMSPLVJJN-UHFFFAOYSA-N CC(CC1)C1N Chemical compound CC(CC1)C1N YYMQZXMSPLVJJN-UHFFFAOYSA-N 0.000 description 1
- VGJONZQRXQOVHR-VAMBABPQSA-N CC[C@H](C[C@@H](C)C(C)CC(C1)C1C(C=C)=C)CN Chemical compound CC[C@H](C[C@@H](C)C(C)CC(C1)C1C(C=C)=C)CN VGJONZQRXQOVHR-VAMBABPQSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010047524 Deoxyribonuclease HindIII Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101000579218 Homo sapiens Renin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010070718 kanamycin nucleotidyltransferase Proteins 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108091007054 readthrough proteins Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/832—Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/848—Escherichia
- Y10S435/849—Escherichia coli
Definitions
- the present invention relates to new gram-positive expression control DNA sequences, to expression vectors containing these DNA sequences, to host cells transformed with these expression vectors and to methods for producing pro- and eukaryotic proteins by using the new expression control DNA sequences, vectors and transformants.
- E. coli Escherichia coli
- E. coli is a member of the gram-negative class of bacteria which contain two layers of membranes enclosing a periplasmic space. Many of the products produced in E. coli are secreted into this periplasmic space, if secreted at all. Few products are secreted outside the living cells into the growth medium.
- Bacillus subtilis (B. subtilis) is a member of the gram-positive class of bacteria which contain only a single layer of bacterial membrane. Thus B. subtilis can produce large amounts of protein which are secreted directly into the growth medium. Moreover, production of proteins in B. subtilis is advantageous since the organism is non-pathogenic and does not produce endotoxins. In addition, B. subtilis has been extensively studied and is the archetype for genetic studies among gram-positive microorganisms.
- the known Bacillus subtilis promoters with the respective base sequences clarified include the veg promoter, tms promoter, pen P promoter (C.P. Moran Jr. et al., Mol. Gen. Genetics 186, 339-346 [1982]), spo VC promoter (C.P. Moran Jr. et al., Nucl. Acids Res. 9, 5979-5990 [1981]), spo VG promoter (C.P. Moran Jr. et al., Cell 25, 783-791 [1981]), ⁇ 29 G3a promoter, O 29 G3b promoter, O 29 G2 promoter, O 29 A1 promoter (C.L. Murray and J.C.
- the present invention specifically provides gram-positive bacterial expression control DNA sequences comprising in the downstream direction of transcription a transcription initiation DNA sequence of gram-negative bacterial origin, a ribosome binding site-encoding DNA sequence of gram-positive or gram-negative bacterial origin optionally operatively linked to a foreign gene encoding prokaryotic or eukaryotic polypeptides, and a transcription termination DNA sequence of gram-negative or gram-positive bacterial origin.
- This invention also provides a process for the manufacture of such expression control DNA sequences, which process comprises combining in the downstream direction (5' to 3') a transcription initiation DNA sequence of gram-negative bacterial origin, a ribosome binding site-encoding DNA sequence of gram-positive or gram-negative origin, and a transcription termination DNA sequence of gram-negative or gram-positive bacterial origin to a functional unit by techniques of DNA recombination well-known in the art.
- a transcription initiation DNA sequence (promoter) of gram-negative bacterial origin with a ribosome binding site-encoding DNA sequence of gram-negative bacterial origin and a transcription termination DNA sequence of gram-positive bacterial origin.
- E EcoRI; Sm: SmaI; B: BamHI; S: Sa1I; P: PstI; H: HindIII; Xh: XhoI; X: XbaI; K: KpnI; Pv: PvuII; A: AccI: Sp: SphI; Bg: Bg1II; D: DraI;
- kan Structural gene for kanamycin nucleotidyl transferase
- dhfr Structural gene for mouse dihydrofolate reductase
- bla Structural gene for beta lactamase
- DHFR Dihydrofolate Reductase protein
- ori+ Gram positive origin of replication
- ori- Gram negative origin of replication
- SRBS Portable ribosome Binding Site-encoding synthetic DNA sequence
- T1, T2, T7 Transcriptional terminator to, T1, T2, T7;
- FIG. 1 Construction of the basic E. coli/B. subtilis shuttle vector p602/5, containing gram-positive (ori+) and gram-negative (ori-) origins of replication, together with drug resistance markers kanamycin (kan) and chloramphenicol. As such, this plasmid confers kanamycin resistance in both E. coli and B. subtilis. Chloramphenicol resistance is achieved through insertion of promoter-containing fragments between the EcoRI (E) and HindIII (H) sites.
- E. coli cat gene presented here has its natural ribosome binding site-encoding DNA sequence.
- subtilis a single fusion CAT protein is produced, originating from the ribosome binding site-encoding DNA sequences SRBSI or SRBSII. Plasmids p602/7, p602/25, p602/7RBSI and p602/7RBSII all confer chloramphenicol resistance in E. coli and B. subtilis.
- FIG. 3 Construction of vectors p25RBSI, p25RBSII and p25*RBSII containing the coliphage T5 promoter P G 25 combined with the ribosome binding site-encoding synthetic DNA sequences SRBSI or SRBSII.
- B. subtilis cells containing the vector p25RBSI synthesize a single CAT fusion protein, originating in the immediate downstream vicinity of SRBSI.
- B. subtilis cells containing the vector p25RBSII synthesize two fusion CAT proteins, originating at the immediate downstream vicinity of SRBSII, as well as a longer fusion protein originating from a ribosome binding site in the immediate vicinity of P G 25.
- Protein synthesis originating from this additional ribosome binding site was eliminated by providing a translational termination codon upstream from SRBSII, resulting in the vector p25*RBSII.
- Cells containing p25*RBSII now synthesize a single fusion CAT protein, originating from SRBSII.
- FIG. 4 Total proteins synthesized in B. subtilis strain BR151 containing the expression vectors p25RBSI, p25RBSII and p25*RBSII.
- the position of the CAT protein originating from SRBSI or SRBSII is indicated ⁇ CAT ⁇ ; the additional fusion CAT protein from cells harbouring p25RBSII is indicated ⁇ f-CAT ⁇ .
- LYS indicates lysozyme, which is added externally to aid cell lysis.
- FIG. 5 Diagramatic representation of CAT proteins synthesized in B. subtilis containing the vectors p25RBSI, p25RBSII and p25*RBSII.
- An in-frame translational stop codon ( ) prevents read through protein synthesis into the cat gene from P G 25 RBS.
- Such an in-frame stop codon is absent in the construction p25RBSII; consequently, cat proteins arise from RBS and SRBSII.
- Modification of the HindIII site in p25*RBSII introduces an in-frame stop codon, and, as a consequence, yields a single CAT protein from SRBSII.
- FIG. 6 In vitro transcriptional analysis of the promoters presented in Table 1.
- the notations ⁇ Ec ⁇ and ⁇ Bs ⁇ indicate analysis with E. coli and B. subtilis RNA polymerase, respectively, and the figures in conjunction with these notations give the salt concentration at which the transcription was performed.
- ⁇ ori ⁇ and ⁇ bla ⁇ transcripts arise from the vector into which the promoters were cloned.
- the panel indicated ⁇ veg ⁇ represents transcription of solely the B. subtilis veg promoter (Le Grice, S. F. J. and Sonenshein, A. L. J. Mol.Biol., 162, 551-564, 1982).
- ⁇ veg ⁇ indicated at the side of the panel indicates transcription of internally supplied veg promoter DNA.
- M molecular weight marker
- FIG. 7 Construction of the shuttle vectors p602/18 and p602/19, containing the coliphage T5 promoter P N 25 operably linked to either the the synthetic ribosome binding site-encoding DNA sequence RBSII, 9A (p602/18) or RBSII, 3A+5A (p602/19). Insertion of the synthetic ribosome binding site-DNA encoding sequences leads, in both cases, to synthesis of a fusion CAT protein initiating in the immediate vicinity of the synthetic ribosome binding site and terminating at the natural translational stop codon of the cat gene. Plasmids p602/18 and 602/19 both confer chloramphenicol resistance on B. subtilis.
- FIG. 8 Construction of the shuttle vectors p602/20 and p602/21, containing the coliphage T5 promoter P N 25 operably linked to the synthetic ribosome binding site-encoding DNA sequences RBSII (p602/20) or RBSII,3A+5A (p602/21). Insertion of the synthetic ribosome binding site-DNA encoding sequences leads, in both cases, to synthesis of a fusion DHFR protein, initiating in the immediate vicinity of the synthetic ribosome binding site and terminating at the natural translational termination codon of the dhfr gene.
- B. subtilis cells containing 602/20 or 602/21 are resistant to 10 ⁇ g/ml trimethoprim.
- FIG. 9 Total proteins synthesised in B. subtilis strain BR151 containing the plasmids p602/18, p602/19, p602/20 and p602/21.
- ⁇ Cell ⁇ denotes protein synthesis from plasmid-free cells.
- CAT synthesis from p25*RBSII has been included.
- the positions of the fusion CAT protein CAT* (from p602/18 and p602/19) and fusion DHFR protein (from p602/20 and p602/21) have been indicated.
- bacterial origin used in connection with transcription initiation DNA sequences comprises (a) naturally occurring bacterial transcription initiation sequences and functional variations thereof including substitutions or inversions of single or several nucleotides and repeats of such transcription initiation DNA sequences and (b) chemically synthesized (synthetic) transcription DNA sequences capable of initiating transcription in bacteria.
- bacterial origin used in connection with ribosome binding site-encoding DNA sequences comprises (a) naturally occurring bacterial ribosome binding site-encoding DNA sequences and functional variations thereof including substitutions or inversions of single or several nucleo-tides and (b) chemically synthesized (synthetic) ribosome binding site-encoding DNA sequences capable of initiating translation in bacteria.
- bacterial origin used in connection with transcription terminationDNA sequences comprises (a) naturally occurring bacterial transcription termination DNA sequences and functional variations thereof including substitutions or inversions of single or several nucleotides and repeats of such transcription termination DNA sequences and (b) chemically synthesized (synthetic) transcription termination DNA sequences capable ofterminating transcription in bacteria.
- genes encoding prokaryotic or eukaryotic proteins can be expressed in Bacillus, particularly B. subtilis, and othergram-positive organisms under the transcriptional control of coliphage T5 or T7-derived promoters and E. coli-derived terminators.
- T5 and T7 promoters are defined as promoter function-mediating DNA sequences occurring in genomes of the coliphage T5 and T7 family and functional combinations derived from such sequences.
- T5 promoters useful in the present invention are those of the "preearly” “early” and “late” expression class of the phage, especially the sequencesdescribed in the dissertation of R. Gentz, Universitat Heidelberg, 1984: P J 5, P N 25, P N 26, P D/E 20, P G 5, P G 20, P G 22, P G 25, P G 28, P K 28a, P K 28b.
- the T7 promoters useful in the present invention include the "early" expression class of the phage, especially the promoters A1 and A2 (Hawley,D.K. and McClure, W.D., Nucleic Acids Res. 11, 2237-2255 [1983]).
- Table I shows the nucleotide sequence of the promoters used in the present invention. The sequence between -50 and +10 is presented, within which the -35 hexamers and upstream A:T-rich regions are boxed, while the -10 hexamers are overlined.
- the ribosome binding site-encoding DNA sequence which is necessary for the initiation of translation in a host cell consists of (1) an ATG translation initiation codon for the amino acid methionine, (2) a sequenceof 4 to 12 bases which are complementary to bases at the 3'-end of 16s ribosomal RNA and which is known as the Shine Dalgarno (SD) sequence and (3) a sequence of bases between these two known as the linker region.
- SD Shine Dalgarno
- the ribosome binding site-encoding DNA sequences used in the present invention and forming part of it may be provided by ribosome binding site-encoding sequences of gram-positive or gram-negative origin capable of functioning in Bacillus, particularly B. subtilis, and other gram-positive organisms, inclusive of several known ones (J.R. McLaughlin et al., J. Biol. Chem. 256, 11283-11291 [1981]; C.P. Moran Jr. et al., Mol. Gen. Genetics 186, 339-346 [1982]).
- SRBS portable ribosome binding site-encoding synthetic RNA sequences
- SRBSs have been constructed in a form so that they can function in conjunction with any desired gene encoding prokaryotic or eukaryotic polypeptides in Bacillus, particularly B. subtilis, and other gram-positive organisms. The ability to so function renders the SRBS "portable”.
- the transcription termination DNA sequence may be provided by terminators of gram-negative bacterial origin capable of functioning in Bacillus, particularly B. subtilis, and other gram-positive organisms.
- the preferredgram-negative terminators used in this invention include the E. coli-derived terminators t o (M. Rosenberg et al., Proc. Natl. Acad. Sci. U.S.A. 73, 717-721 [1976], T1, T2 (J. Brosius et al., J. Mol. Biol. 148, 107-127 [1981]and T7 (J.J. Dunn and Studier, F.W., Nucleic Acids Res.8, 2119-2132 [1980].
- the transcription initiation DNA sequences, the portable ribosome binding site-encoding sequences and the transcription termination sequences of thepresent invention can be obtained in accordance with methods well-known in DNA chemistry including total chemical synthesis of the respective DNA sequence, e.g., in a nucleotide synthesizer.
- the invention further comprises expression vectors capable of directing expression of a gene encoding pro- and eukaryotic proteins in a bacillus, particularly B. subtilis or another gram-positive organism transformed therewith, containing (a) a gram-positive bacterial expression control DNAsequence having in the downstream direction of transcription the following units: at least one transcription initiation DNA sequence of gram-negativebacterial origin combined with a ribosome binding site encoding DNA sequence of gram-positive or gram-negative origin, optionally a foreign gene encoding prokaryotic or eukaryotic polypeptides and a transcription termination DNA sequence, (b) at least one vector origin of replication and (c) at least one antibiotic resistance gene as well as a process for the manufacture of such expression vectors.
- expression vectors capable of directing expression of a gene encoding pro- and eukaryotic proteins in a bacillus, particularly B. subtilis or another gram-positive organism transformed therewith, containing (a) a gram-positive bacterial
- the transcription initiation DNA sequence may be provided by a gram-negative promoter.
- the preferred gram-negative promoters used are coliphage T5 or coliphage T7 promoters with the formulae indicated in Table 1.
- the origin of replication may be of gram-negative and/or gram-positive origin and thus the expression vectors can be employed as shuttle vectors (Ehrlich, S.D., Proc. Natl. Acad. Sci. U.S.A. 75, 1433-1436 [1978]; Kreft,J. et al., Molec, gen. Genet. 162, 59-67 [1978]; Michel, B. et al., Gene 12, 147-154 [1980]), which can replicate both in E. coli and Bacillus, especially B. subtilis.
- Preferred expression vectors using ribosome binding site-encoding synthetic DNA sequences ligated to a coliphage T5 promoter and capable of replicating both in E. coli and B. subtilis are described in Examples 4, 5 and 7 to 10, infra.
- the expression vectors of the present invention can be constructed using techniques of DNA recombination that are well known in the art (see laboratory manual "Molecular Cloning” by Maniatis et al., Cold Spring Harbor Laboratory, 1982) comprising the steps of:
- Plasmids of the p602 and p25 families are specific examples of plasmidic shuttle vectors of the present invention. Their preparation is described in more detail in Examples 1 to 5 and 7 to 10.
- B. subtilis strains containing the especially preferred plasmids of the p25 family (B. subtilis BR151 transformed with p25RBSI; p25RBSII; p25*RBSII) were deposited at Deutsche Sammlung von Mikroorganismen (DSM) in Gottingen on June 20, 1985, the accession Nos. being DSM 3350, DSM 3351 and DSM 3352, respectively.
- B. subtilis strains containing the especially preferred plasmids of the p602 family B.
- subtilis BR 151 transformed with p602/18; p602/19; p602/20; p602/21) were deposited at Deutsche Sammlung von Mikroorganismen (DSM) in Gottingen on May 14, 1986, the accession Nos. being DMS 3723, DSM 3724, DSM 3725 and DSM 3726, respectively.
- Foreign genes that may be inserted into the expression vectors of this invention may be selected from a large variety of genes (DNA genes or DNA copies of RNA genes) that encode prokaryotic or eukaryotic polypeptides invivo and in vitro.
- genes may encode enzymes, hormones, polypeptides with immuno-modulatory, anti-viral or anti-cancer properties,antibodies, antigens, and other useful polypeptides of prokaryotic or eukaryotic origin.
- the preferred foreign genes used in this invention are the genes encoding E. coli chloramphenicol acetyltransferase (cat) and mouse dihydrofolate reductase (dhfr).
- proteins which can be expressed by using the improved expression control system of the present invention are dihydrofolate reductase, chloramphenicol acetyltransferase, malaria surface antigens, lymphokins like IL-2, interferons alpha, beta and gamma, insulin and insulin precursors, growth hormones, tissue plasminogen activator, human renin or HTLV-III proteins.
- Methods for expressing genes encoding prokaryotic or eukaryotic proteins using the expression vectors, especially shuttle vectors, of this invention are well-known (Maniatis et al., supra). They include transforming an appropriate host with an expression vector having the desired DNA sequence operatively inserted into an expression control DNA sequence of the present invention, culturing the host under appropriate conditions of growth and isolating the desired polypeptide from the culture. Those of skill in the art may select from these known methods those that are most effective for a particular gene expression without departing from the scope of this invention.
- a particular host for use in this invention is dependent upon a number of factors recognized by the art. These include, for example, compatability with the chosen expression vector, toxicity of the proteins encoded for by the hybrid plasmid, ease of recovery of the desired protein, expression characteristics, biosafety and costs.
- examples of useful bacterial hosts are gram-negative and gram-positive bacteria, especially strains of E. coli and B. subtilis.
- the most preferred host cell of this invention is B. subtilis BR 151 (stocked at The Bacillus Genetic Stock Center under BGSC No. 1A40).
- B. subtilis strains such as B. subtilis BD 170 (stocked at The Bacillus Genetic Stock Center under BGSC No. 1A 42) and B.subtilis JH646 (stocked at The Bacillus Genetic Stock Center under BGSC No.1S9) can also be used.
- Transformation of DNA into cells of B. subtilis was performed as described by S. Contente and obnau, D. (Mol. Gen. Genet 167, 251-258 [1979]).
- RNA polymerases of E. coli and B. subtilis were performed in 50 ul assays of the following composition; 40 mM Tris/HC1, pH7.9, 10 mM MgC1 2 , 0,1 mM DTT, 0,1 mM EDTA, 50-200 mM NaC1, 10% (v/v) glycerol, 150 ⁇ M ATP, GTP, CTP, 50 ⁇ M UTP, 5 uCi 32 P-UTP ( ⁇ 3000 Ci/m mole, Amersham Buchler, Braunschweig), 0,05 p mole endonucleolytically-cleaved DNA, and 0,25 p mole RNA polymerase.
- RNA polymerase Reactionswere initiated by addition of RNA polymerase and allowed to proceed for between 1 and 5 mins at 37° C. Synthesized RNA was isolated by repeated ethanol precipitation and analyzed by high voltage gel electrophoresis through 0.4 mm thick 5 or 8% polyacrylamide gels containing 8M urea. Following electrophoresis, gels were dried and subjected to autoradiography using Kodak X-OMAT XAR 5 film at room temperature.
- the KpnI/XbaI fragment was subsequently purified from the acrylamide gel slice.
- (III) Five ⁇ g of plasmid pDS5 were digested to completion with the endonucleases EcoRI and XbaI and then separated by electrophoresis through a 1% low melting temperature agarose gel containing 1 ⁇ g/ml ethidium bromide. Following electrophoresis, the DNAbands were visualized by fluorescence, and an approximately 900 bp EcoRI/SbaI fragment was excised. The EcoRI/XbaI fragment was subsequently purified from the low melting temperature agarose.
- the ligation products were transformed into E. coli strain AB1157, and transformed cells were selected on LB agar containing 50 ⁇ g/ml chloramphenicol. Chloramphenicol-resistant colonies were analyzed to verify the insertion of promoter PvII into the plasmid p602/5. The resultant plasmid was designated p602/7.
- II Two ⁇ g of plasmid p602/7 were digested to completion with the endonuclease HindIII.
- the portable ribosome binding site-encoding synthetic DNA sequence SRBSI, having the sequence ##STR12## was ligated into the HindIII site.
- the ligation products were transformed into E.
- Plasmid DNA thus characterized was designated p602/7RBSI.
- Purified p602/7RBSI DNA was thereafter transformed into B. subtilis strain BR151, and chloramphenicolresistant colonies (in this case, colonies resistant to10 ug/ml chloramphenicol) were assayed as mentioned in (II) a) and b) to verify the utility of SRBS I in B. subtilis.
- Plasmid p602/7RBSI was digested to completion with HindIII and SphI and purified from SRBSI by electrophoresis through a 1% low melting temperature agarose gel containing 1 ⁇ g/ml ethidium bromide. Following electrophoresis, the DNA was visualized by fluorescence and excised from the gel. The DNA was subsequently purified from the agarose.
- a portable ribosome binding site-encoding synthetic DNA sequence, designated SRBSII, and having the sequence ##STR13## was ligated with HindIII/SphI cleaved p602/7RBSI DNA.
- Plasmid DNA thus characterized was designated p602/7RBSII.
- Plasmid p602/7RBSII was introduced into competent cells of B. subtilis strain BR151, and transformed cells were selected on LB agar containing 10 ug/ml chloramphenicol. Chloramphenicol-resistant colonies were analyzed for the utility of SRBSII in B. subtilis as described in Step (III) a) and b).
- Theconstruction of vectors p602/7RBSI and p602/7RBSII is illustrated in FIG. 2.
- Plasmid DNA was isolated from E. coli harbouring p25RBSI and transformed into competent cultures of B. subtilis strain BR151, and transformed cells were selected on LB agar containing 10 ⁇ g/ml chloramphenicol. Plasmid DNA was isolated from chloramphenicol resistant colonies, and the structure of plasmid p25RBSI in B. subtilis was verifiedby restriction endonuclease analysis.
- Plasmid DNA was isolated from chloramphenicol resistant colonies, and the presence of both the coliphage T5 promoter P G 25 and the synthetic ribosome binding site-encoding DNA sequence SRBSII were verified by restriction endonuclease analysis. Plasmid DNA thus characterized was designated p25/RBSII. The construction of plasmid p25RBSII is illustrated in FIG. 3.
- FIG. 4 Protein synthesis in B. subtilis containing the vector p25RBSII is illustrated in FIG. 4. It was discovered here that the EcoRI fragment harbouring the promoter P G 25 contains an accessory ribosome binding site which produces a fusion protein extending to the end of the cat gene. The immediate effect is to drastically reduce the efficiency of RBSII. As aconsequence, the protein reading frame from the ribosome binding site in the immediate vicinity of P G 25 was altered as follows, to maximize protein synthesis from SRBSII:
- (V) PLasmid p25*RBSII was introduced into competent cultures of B. subtilisstrain BR151, and transformed cells were selected on LB agar containing 10 ⁇ g/ml chloramphenicol. Plasmid DNA was then isolated from chloramphenicol resistant colonies and its structural identity to p25*RBSII isolated from E. coli was determined by restriction endonucleaseanalysis.
- Table 1 indicates the promoters which were used. Their potential was determined by in vitro ⁇ run-off ⁇ transcription, the results of which are presented in FIG. 6. In each case, promoter utilization by B. subtilis ⁇ 55 RNA polymerase was determined as a function of increasing ionic strength and compared with its efficiency when transcribed with E. coli RNA polymerase in 200 mM NaC1. Each transcription assay contained, inaddition to the promoter in question, stoichiometric amounts of the B. subtilis veg promoter, previously shown to be efficiently utilized by B. subtilis ⁇ 55 RNA polymerase (Moran Jr. et al., Mol. Gen. Genetics 186, 339-346 [1982]).
- subtilis RNA polymerase initiates transcription not only from the promoters in question, but also from the ⁇ bla ⁇ and ⁇ ori ⁇ promoters of the pBR322 vector DNA (for preliminary studies, all promoters were inserted into pBR322 derived vectors: these plasmids were subsequently cleaved to yield a constant 350 nucleotide ⁇ bla ⁇ transcript and a variable length transcript from the coliphage T5 promoter in question). As the salt concentration is raised, promoter selection becomes clearly evident, partitioning between the veg and coliphage T5 promoters.
- coliphage T5 promoters or the A1 promoter of coliphage T7, can be substituted for the P G 25 promoter of the vector p25*RBSII (FIG. 3), and CAT synthesis inB. subtilis can be determined.
- Plasmid DNA was purified from transformants resistant to 10 ⁇ g/ml kanamycin and 10 ug/ml chloramphenicol and assayed for the presence of the 1.0 Kb XhoI/XbaI fragment. Plasmid DNA thus characterized was designated p602/19. The construction of p602/19 is illustrated in FIG. 7.
- Plasmid DNA was purified from transformants resistant to 10 ⁇ g/ml kanamycin and 10 ug/ml trimethoprim and analyzed for the presence of the 2.0 Kb XhoI/XbaI fragment. Plasmid DNA thus characterized was designated p602/20. The construction of p602/20 is illustrated in FIG. 8.
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8517071 | 1985-07-05 | ||
GB858517071A GB8517071D0 (en) | 1985-07-05 | 1985-07-05 | Gram-positive expression control sequence |
Publications (1)
Publication Number | Publication Date |
---|---|
US4868111A true US4868111A (en) | 1989-09-19 |
Family
ID=10581857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/875,437 Expired - Fee Related US4868111A (en) | 1985-07-05 | 1986-06-17 | Gram-positive expression control sequences |
Country Status (12)
Country | Link |
---|---|
US (1) | US4868111A (fr) |
EP (1) | EP0207459B1 (fr) |
JP (2) | JP2632809B2 (fr) |
AT (1) | ATE62020T1 (fr) |
AU (1) | AU594349B2 (fr) |
CA (1) | CA1316850C (fr) |
DE (1) | DE3678343D1 (fr) |
DK (1) | DK175206B1 (fr) |
GB (1) | GB8517071D0 (fr) |
IE (1) | IE59165B1 (fr) |
IL (1) | IL79291A (fr) |
NZ (1) | NZ216688A (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998013472A1 (fr) * | 1996-09-25 | 1998-04-02 | Robinson Douglas H | Procede de production de bacteries contenant des genes eucaryotes |
WO1999016858A1 (fr) * | 1997-09-30 | 1999-04-08 | Human Genome Sciences, Inc. | Sequences de regulation de l'expression |
US6146848A (en) * | 1998-07-23 | 2000-11-14 | The Hong Kong University Of Science & Technology | Bacterial expression system |
US20030143685A1 (en) * | 2001-10-26 | 2003-07-31 | Id Biomedical Corporation Of Washington | Efficient protein expression system |
US6924105B2 (en) * | 2000-10-25 | 2005-08-02 | Fuji Photo Film Co., Ltd. | Method of analyzing double stranded DNA |
US20110033438A1 (en) * | 2006-10-18 | 2011-02-10 | Periness Ltd. | Method and pharmacological composition for the diagnosis and treatment of male |
WO2016073079A2 (fr) | 2014-09-26 | 2016-05-12 | Yale University | Compositions et procédés pour le confinement biologique de microorganismes |
US11149280B2 (en) | 2019-10-29 | 2021-10-19 | Yale University | Engineering organisms resistant to viruses and horizontally transferred genetic elements |
WO2023178316A2 (fr) | 2022-03-17 | 2023-09-21 | Yale University | Compositions et méthodes d'expression d'éléments génétiques synthétiques chez divers micro-organismes |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266474A (en) * | 1987-06-24 | 1993-11-30 | Genentech, Inc. | Balanced inducible transcription system |
EP0303925B1 (fr) * | 1987-08-17 | 1995-06-07 | F. Hoffmann-La Roche Ag | Séquence très répressible pour le contrôle de l'expression |
US5726042A (en) * | 1988-04-07 | 1998-03-10 | Abbott Laboratories | Expression of heterologous proteins in Bacillus megaterium utilizing sporulation promoters of Bacillus subtilis |
GB8811761D0 (en) * | 1988-05-18 | 1988-06-22 | Thomae Gmbh Dr K | Biosynthetic process for preparation of chemical compounds |
US7049102B1 (en) | 1989-09-22 | 2006-05-23 | Board Of Trustees Of Leland Stanford University | Multi-gene expression profile |
FR2679568B1 (fr) * | 1991-07-22 | 1994-09-02 | Pasteur Institut | Nouveau type de replicon gram-positif - construction de vecteurs recombinants le contenant. |
GB2278358B (en) | 1992-02-27 | 1995-07-26 | Lynxvale Ltd | Heterologous gene expression in Lactococcus,and the expression products therefrom |
US5629205A (en) * | 1995-05-19 | 1997-05-13 | Allelix Biopharmaceuticals Inc. | Promoters for gene expression |
US6720174B1 (en) | 1999-01-28 | 2004-04-13 | Novozymes A/S | Phytases |
JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
CA2545610C (fr) | 2003-11-19 | 2014-03-25 | Dow Global Technolgies Inc. | Bacterie pseudomonas fluorescens auxotrophique pour expression de proteine recombinante |
EP2327718B1 (fr) | 2003-11-21 | 2016-03-23 | Pfenex, Inc. | Systèmes d'expression ameliorés à sécrétion du système SEC |
KR20120076377A (ko) | 2004-01-16 | 2012-07-09 | 다우 글로벌 테크놀로지스 엘엘씨 | 슈도모나스 플루오레센스에서의 포유류 단백질의 발현 |
CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
GB0602173D0 (en) * | 2006-02-03 | 2006-03-15 | Avecia Ltd | Expression system |
KR101491867B1 (ko) | 2007-01-31 | 2015-02-10 | 피페넥스 인크. | 증가된 발현을 위한 박테리아 리더 서열 |
WO2008134461A2 (fr) | 2007-04-27 | 2008-11-06 | Dow Global Technologies, Inc. | Procédé pour rapidement cribler des hôtes microbiens et identifier certaines souches ayant un rendement et/ou une qualité d'expression des protéines hétérologues améliorés |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
EP2430164B1 (fr) | 2009-05-11 | 2017-07-19 | Pfenex, Inc. | Production de protéine de recombinaison faisant intervenir des méthodes de sélection non antibiotiques et l'incorporation d'acides aminés non naturels |
WO2011109556A2 (fr) | 2010-03-04 | 2011-09-09 | Pfenex Inc. | Procédé pour la production de la protéine interféron recombinante soluble sans dénaturation |
EP2553102B1 (fr) | 2010-03-30 | 2015-12-09 | Pfenex Inc. | Expression de protéines de toxines recombinantes en forte quantité |
WO2011123570A2 (fr) | 2010-04-01 | 2011-10-06 | Pfenex Inc. | Procédés pour la production de g-csf dans une cellule hôte de pseudomonas |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
CA2966358C (fr) | 2014-12-01 | 2021-12-07 | Pfenex Inc. | Partenaires de fusion pour la production de peptides |
WO2019083793A1 (fr) | 2017-10-27 | 2019-05-02 | Pfenex Inc. | Procédé de production d'erwinia asparaginase de recombinaison |
AU2018354069A1 (en) | 2017-10-27 | 2020-06-11 | Pelican Technology Holdings, Inc. | Bacterial leader sequences for periplasmic protein expression |
US20220313798A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4495280A (en) * | 1981-05-20 | 1985-01-22 | The Board Of Trustees Of The Leland Stanford Jr. University | Cloned high signal strength promoters |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR81701B (fr) | 1983-01-18 | 1984-12-12 | Lilly Co Eli | |
EP0115936A1 (fr) * | 1983-01-24 | 1984-08-15 | Kabushiki Kaisha Yakult Honsha | Plasmides chimériques |
-
1985
- 1985-07-05 GB GB858517071A patent/GB8517071D0/en active Pending
-
1986
- 1986-06-17 US US07/875,437 patent/US4868111A/en not_active Expired - Fee Related
- 1986-06-27 DE DE8686108774T patent/DE3678343D1/de not_active Expired - Lifetime
- 1986-06-27 AT AT86108774T patent/ATE62020T1/de not_active IP Right Cessation
- 1986-06-27 EP EP86108774A patent/EP0207459B1/fr not_active Expired - Lifetime
- 1986-06-27 NZ NZ216688A patent/NZ216688A/xx unknown
- 1986-06-30 AU AU59385/86A patent/AU594349B2/en not_active Expired
- 1986-06-30 IL IL79291A patent/IL79291A/xx not_active IP Right Cessation
- 1986-07-04 DK DK198603206A patent/DK175206B1/da not_active IP Right Cessation
- 1986-07-04 IE IE180686A patent/IE59165B1/en not_active IP Right Cessation
- 1986-07-04 CA CA000513094A patent/CA1316850C/fr not_active Expired - Lifetime
- 1986-07-04 JP JP61157771A patent/JP2632809B2/ja not_active Expired - Lifetime
-
1996
- 1996-07-16 JP JP8185740A patent/JP2887248B2/ja not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4495280A (en) * | 1981-05-20 | 1985-01-22 | The Board Of Trustees Of The Leland Stanford Jr. University | Cloned high signal strength promoters |
Non-Patent Citations (28)
Title |
---|
Band et al., Gene 26: 313 (1983). * |
Briat et al., Proc. Natl. Acad. Sci. USA 81: 7373 (1984). * |
Brosius et al., J. Mol. Biol. 148: 107 (1981). * |
De Boer et al., Biochem. Soc. Symp. 48: 233 (1983). * |
Dunn et al., Nucleic Acids Res. 8: 2119 (1980). * |
Ehrlich, S. D., Proc. Natl. Acad. Sci. USA 75: 1433 (1978). * |
Gilman et al., Nucleic Acids Res. 9: 5991 (1981). * |
Grange et al., Nucleic Acids Res. 12: 3585 (1984). * |
Gryczan et al., J. Bacteriol. 134: 318 (1978). * |
Hawley et al., Nucleic Acids Res. 11: 2237 (1983). * |
Jay et al., Proc. Natl. Acad. Sci. USA 81: 2290 (1984). * |
Kreft et al., Molec. Gen. Genet. 162: 59 (1978). * |
Lee et al., J. Mol. Biol. 139:407 (1980). * |
Lee et al., Molec. Gen. Genet. 180: 57 (1980). * |
McLaughlin et al., J. Biol. Chem. 256:11283 (1981). * |
Michel et al., Gene 12:147 (1980). * |
Moran, Jr. et al., Cell 25:783 (1981). * |
Moran, Jr. et al., Mol. Gen. Genet. 186: 339 (1982). * |
Moran, Jr. et al., Nucleic Acids Res. 9:5979 (1981). * |
Murray et al., J. Biol. Chem. 257: 1053 (1982). * |
Nunberg et al., 1980, Cell, 19: 355 364. * |
Nunberg et al., 1980, Cell, 19: 355-364. |
Rosenberg et al., Proc. Natl. Acad. Sci. USA 73:717 (1976). * |
Schoner et al., Gene 22:47 (1983). * |
Simons et al., 1984, Gene, 28: 55 64. * |
Simons et al., 1984, Gene, 28: 55-64. |
Stueber et al., EMBO J. 3:3143 (1984). * |
Zukowski et al., Proc. Natl. Acad. Sci. USA 80: 1101 (1983). * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022730A (en) * | 1994-06-17 | 2000-02-08 | Robinson; Douglas H. | Methods for the isolation of bacteria containing eukaryotic genes |
WO1998013472A1 (fr) * | 1996-09-25 | 1998-04-02 | Robinson Douglas H | Procede de production de bacteries contenant des genes eucaryotes |
WO1999016858A1 (fr) * | 1997-09-30 | 1999-04-08 | Human Genome Sciences, Inc. | Sequences de regulation de l'expression |
US6194168B1 (en) * | 1997-09-30 | 2001-02-27 | Human Genome Sciences, Inc. | Expression control sequences |
US6420138B1 (en) | 1997-09-30 | 2002-07-16 | Human Genome Sciences, Inc. | Expression control sequences |
US6146848A (en) * | 1998-07-23 | 2000-11-14 | The Hong Kong University Of Science & Technology | Bacterial expression system |
US6924105B2 (en) * | 2000-10-25 | 2005-08-02 | Fuji Photo Film Co., Ltd. | Method of analyzing double stranded DNA |
US6939959B2 (en) | 2001-10-26 | 2005-09-06 | Id Biomedical Corporation Of Washington | Efficient protein expression system |
US20030143685A1 (en) * | 2001-10-26 | 2003-07-31 | Id Biomedical Corporation Of Washington | Efficient protein expression system |
US20050287642A1 (en) * | 2001-10-26 | 2005-12-29 | Id Biomedical Corporation Of Washington | Efficient protein expression system |
US20070148731A9 (en) * | 2001-10-26 | 2007-06-28 | Id Biomedical Corporation Of Washington | Efficient protein expression system |
US7528245B2 (en) | 2001-10-26 | 2009-05-05 | Id Biomedical Corporation Of Washington | Efficient protein expression system |
US20110033438A1 (en) * | 2006-10-18 | 2011-02-10 | Periness Ltd. | Method and pharmacological composition for the diagnosis and treatment of male |
US9149513B2 (en) | 2006-10-18 | 2015-10-06 | Periness Ltd. | Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
WO2016073079A2 (fr) | 2014-09-26 | 2016-05-12 | Yale University | Compositions et procédés pour le confinement biologique de microorganismes |
US11408007B2 (en) | 2014-09-26 | 2022-08-09 | Yale University | Compositions and methods for biocontainment of microorganisms |
US11149280B2 (en) | 2019-10-29 | 2021-10-19 | Yale University | Engineering organisms resistant to viruses and horizontally transferred genetic elements |
WO2023178316A2 (fr) | 2022-03-17 | 2023-09-21 | Yale University | Compositions et méthodes d'expression d'éléments génétiques synthétiques chez divers micro-organismes |
Also Published As
Publication number | Publication date |
---|---|
IL79291A (en) | 1991-06-30 |
GB8517071D0 (en) | 1985-08-14 |
DK320686A (da) | 1987-01-06 |
DK175206B1 (da) | 2004-07-12 |
IL79291A0 (en) | 1986-09-30 |
DK320686D0 (da) | 1986-07-04 |
IE59165B1 (en) | 1994-01-12 |
EP0207459A3 (en) | 1988-07-06 |
IE861806L (en) | 1987-01-05 |
ATE62020T1 (de) | 1991-04-15 |
EP0207459A2 (fr) | 1987-01-07 |
AU5938586A (en) | 1987-01-08 |
AU594349B2 (en) | 1990-03-08 |
CA1316850C (fr) | 1993-04-27 |
JPH10229878A (ja) | 1998-09-02 |
JP2632809B2 (ja) | 1997-07-23 |
DE3678343D1 (de) | 1991-05-02 |
JP2887248B2 (ja) | 1999-04-26 |
NZ216688A (en) | 1990-06-26 |
EP0207459B1 (fr) | 1991-03-27 |
JPS6214786A (ja) | 1987-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4868111A (en) | Gram-positive expression control sequences | |
US6808896B2 (en) | Method for stable chromosomal multi-copy integration of genes | |
Mullin et al. | Cloning of the Escherichia coli dnaZX region and identification of its products | |
US5024943A (en) | Regulatory region cloning and analysis plasmid for bacillus | |
US5232840A (en) | Enhanced protein production in bacteria by employing a novel ribosome binding site | |
EP0235410B1 (fr) | Système d'expression de procaryotes | |
US5726039A (en) | Vectors and transformed host cells for recombinant protein production at reduced temperatures | |
Kovacevic et al. | Secretion of staphylococcal nuclease by Bacillus subtilis | |
EP0821063B1 (fr) | Production améliorée de riboflavine | |
US4954618A (en) | Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G | |
US4987078A (en) | Plasmid vectors for expression in Escherichia coli and/or Bacillus subtilis | |
US5082773A (en) | Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G | |
Tanaka et al. | prtR enhances the mRNA level of the Bacillus subtilis extracellular proteases | |
US5629205A (en) | Promoters for gene expression | |
US6617130B1 (en) | DNA construct for regulating the expression of a polypeptide coding sequence in a transformed bacterial host cell | |
US6100063A (en) | Procaryotic cell comprising at least two copies of a gene | |
US4994380A (en) | Process for expressing genes by Bacillus brevis | |
US5654169A (en) | Vectors and transformed host cells for recombinant protein production at reduced temperatures | |
IE59562B1 (en) | Method for preparing proteins using transformed lactic acid bacteria | |
EP0186069A2 (fr) | Séquence de contrôle d'expression | |
EP0223156B1 (fr) | Gène sensible à la streptomycine contenant beaucoup de sites de clonage, vecteur de plasmide contenant ce gène et micro-organisme contenant le vecteur | |
Qi et al. | Localization of a new promoter, P5, in the sigA operon of Bacillus subtilis and its regulation in some spo mutant strains | |
US5721137A (en) | Plasmid vector and its use for the production of heterologous proteins | |
EP0174785A1 (fr) | Elément rétrorégulateur positif, plasmide et cellules contenant ledit élément et leur production, méthode pour le renforcement de l'expression génétique utilisant ledit élément et méthode pour le renforcement de la demi-vie de l'ARN utilisant ledit élément | |
Madu et al. | Molecular cloning and in vitro expression of a silent phenoxazinone synthase gene from Streptomyces lividans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOFFMANN-LA ROCHE INC., NUTLEY, NEW JERSEY, A CORP Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:F. HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT;REEL/FRAME:004591/0310 Effective date: 19860804 Owner name: F. HOFFMANN-LA ROCHE & CO., AKTIENGESELLSCHAFT, BA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:BUJARD, HERMANN;LE GRICE, STUART;REEL/FRAME:004591/0344 Effective date: 19860804 Owner name: F. HOFFMANN-LA ROCHE & CO., AKTIENGESELLSCHAFT, SW Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUJARD, HERMANN;LE GRICE, STUART;REEL/FRAME:004591/0344 Effective date: 19860804 |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19970924 |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |